SI3137093T1 - Treatment and prevention of Alzheimer's disease - Google Patents

Treatment and prevention of Alzheimer's disease Download PDF

Info

Publication number
SI3137093T1
SI3137093T1 SI201530145T SI201530145T SI3137093T1 SI 3137093 T1 SI3137093 T1 SI 3137093T1 SI 201530145 T SI201530145 T SI 201530145T SI 201530145 T SI201530145 T SI 201530145T SI 3137093 T1 SI3137093 T1 SI 3137093T1
Authority
SI
Slovenia
Prior art keywords
aluminum
alzheimer
oxyhydroxide
disease
oxihydroxide
Prior art date
Application number
SI201530145T
Other languages
English (en)
Slovenian (sl)
Inventor
Markus Mandler
Achim Schneeberger
Bonin Arne Von
Frank Mattner
Walter Schmidt
Original Assignee
Affiris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris Ag filed Critical Affiris Ag
Publication of SI3137093T1 publication Critical patent/SI3137093T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI201530145T 2014-04-29 2015-04-29 Treatment and prevention of Alzheimer's disease SI3137093T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14166354 2014-04-29
EP14166355 2014-04-29
EP15720059.3A EP3137093B1 (en) 2014-04-29 2015-04-29 Treatment and prevention of alzheimer's disease (ad)
PCT/EP2015/059339 WO2015165966A1 (en) 2014-04-29 2015-04-29 Treatment and prevention of alzheimer's disease (ad)

Publications (1)

Publication Number Publication Date
SI3137093T1 true SI3137093T1 (en) 2018-01-31

Family

ID=53039896

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201530145T SI3137093T1 (en) 2014-04-29 2015-04-29 Treatment and prevention of Alzheimer's disease

Country Status (18)

Country Link
US (1) US10478454B2 (https=)
EP (2) EP3269376B1 (https=)
JP (1) JP6692755B2 (https=)
KR (1) KR102388363B1 (https=)
CN (1) CN106659738B (https=)
AU (1) AU2015254663B2 (https=)
CA (1) CA2946928C (https=)
CY (1) CY1119674T1 (https=)
DK (1) DK3137093T3 (https=)
ES (2) ES2824763T3 (https=)
HR (1) HRP20171896T1 (https=)
HU (1) HUE037501T2 (https=)
LT (1) LT3137093T (https=)
NO (1) NO3137093T3 (https=)
PL (1) PL3137093T3 (https=)
PT (1) PT3137093T (https=)
SI (1) SI3137093T1 (https=)
WO (1) WO2015165966A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102460465B1 (ko) 2014-04-29 2022-10-27 어드밴티지 테라퓨틱스, 인코포레이티드 알츠하이머병（ａｄ）의 치료 및 예방
FI3137094T3 (fi) 2014-04-29 2023-03-20 Advantage Therapeutics Inc Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3440593A (en) * 1993-01-14 1994-08-15 Nelson Arispe Methods and compositions for blocking amyloid protein ion channels
WO1999009981A1 (en) * 1997-08-21 1999-03-04 P.N. Gerolymatos S.A. Use of phanquinone for the treatment of alzheimer's disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
CA2793580A1 (en) * 2010-03-29 2011-10-06 Novartis Ag Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant
KR102460465B1 (ko) * 2014-04-29 2022-10-27 어드밴티지 테라퓨틱스, 인코포레이티드 알츠하이머병（ａｄ）의 치료 및 예방
FI3137094T3 (fi) * 2014-04-29 2023-03-20 Advantage Therapeutics Inc Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen

Also Published As

Publication number Publication date
KR20160145822A (ko) 2016-12-20
PL3137093T3 (pl) 2018-06-29
PT3137093T (pt) 2017-12-19
EP3269376B1 (en) 2020-07-15
CY1119674T1 (el) 2018-04-04
DK3137093T3 (en) 2017-12-11
ES2824763T3 (es) 2021-05-13
CN106659738A (zh) 2017-05-10
HUE037501T2 (hu) 2018-08-28
EP3137093B1 (en) 2017-09-13
EP3269376A1 (en) 2018-01-17
ES2651537T3 (es) 2018-01-29
KR102388363B1 (ko) 2022-04-19
JP2017518275A (ja) 2017-07-06
WO2015165966A1 (en) 2015-11-05
HRP20171896T1 (hr) 2018-02-23
AU2015254663A1 (en) 2016-11-10
CA2946928C (en) 2023-01-31
JP6692755B2 (ja) 2020-05-13
AU2015254663B2 (en) 2020-04-02
LT3137093T (lt) 2017-12-11
NO3137093T3 (https=) 2018-02-10
EP3137093A1 (en) 2017-03-08
US10478454B2 (en) 2019-11-19
US20170049812A1 (en) 2017-02-23
CA2946928A1 (en) 2015-11-05
CN106659738B (zh) 2021-02-09

Similar Documents

Publication Publication Date Title
SI2849758T1 (en) Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
WO2013158680A3 (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
EA201492021A1 (ru) Антительный состав
AR082150A1 (es) N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio
JP2015525763A5 (https=)
MX2012007410A (es) Compuestos antivirales novedosos.
HRP20110800T1 (hr) UPORABA 2-6-(3-AMINO-PIPERIDIN-1-IL)-3-METIL-2,4-DIOKSO-3,4-DIHIDRO-2H-PIRIMIDIN-1-ILMETIL-4-FLUORO-BENZONITRILA ZA LIJEČENJE DIJABETESA, RAKA, AUTOIMUNIH POREMEĆAJA I ZARAZE HIV-om
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
PH12014501620A1 (en) Compositions and methods for the treatment of hepatic diseases and disorders
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
MY169099A (en) Injectable formulation
EP4342473A3 (en) Compounds useful in hiv therapy
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
MA42301B1 (fr) Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone
SI3099307T1 (en) Use of cladribine for the treatment of neuromyelitis of the visual nerve
SI3137093T1 (en) Treatment and prevention of Alzheimer's disease
FI3137094T3 (fi) Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen
HRP20190211T1 (hr) Inhibitor proteina za prijenos kolesterilestera (cetp) i farmaceutski pripravci koji sadrže spomenuti inhibitor za primjenu u liječenju ili prevenciji kardiovaskularnih bolesti
JP2017515812A5 (https=)
JP2019531286A5 (https=)
JP2017514831A5 (https=)
JP2017518275A5 (https=)
JP2015524808A5 (https=)
EP2606885A4 (en) "RENESSANS" MEDICINAL PREPARATION WITH ANTIBACTERIAL, ANTI-ULCER AND IMMUNOMODULATORY ACTION